MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes

Leukemia Research

Volumn 39, Issue 7, 2015, Pages 763-768

  Choi, Ji Seon ^a   Nam, Myung Hyun ^a   Yoon, Soo Young ^a   Kang, Seong Ho ^b  

^a Korea University College of Medicine   (South Korea)

^b Chosun University College of Medicine   (South Korea)

Author keywords

Deregulation; Diagnosis; MDS; MicroRNA; Prognosis

Indexed keywords

MICRORNA; MICRORNA 101 3P; MICRORNA 124 3P; MICRORNA 151A 5P; MICRORNA 194 5P; MICRORNA 29C 3P; MICRORNA 30B 5P; MICRORNA 30D 5P; MICRORNA 320A; MICRORNA 486 5P; MICRORNA 596; MICRORNA 875 5P; UNCLASSIFIED DRUG; MIRN194 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CHROMOSOME 1Q; CHROMOSOME 8; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION; GENETICS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOPHYSIOLOGY;

ADULT; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84930377843     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.04.013     Document Type: Article

References (19)

1. Yin C.C., Medeiros L.J., Bueso-Ramos C.E. Recent advances in the diagnosis and classification of myeloid neoplasms - comments on the 2008 WHO classification. Int J Lab Hematol 2010, 32:461-476.
2. Jung S.W., Lee S.Y., Jekarl D.W., et al. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution. Leuk Res 2011, 35:735-740.
3. Lee D.S., Kim S.H., Seo E.J., et al. Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. Cancer Genet Cytogenet 2002, 132:97-101.
4. Irons R.D., Wang X., Gross S.A., et al. Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications. Leuk Res 2006, 30:769-775.
5. Wang H., Wang X., Xu X., Lin G. Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study. Ann Hematol 2010, 89:535-544.
6. Gangaraju V.K., Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009, 10:116-125.
7. Kloosterman W.P., Plasterk R.H. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006, 11:441-450.
8. Calin G.A., Sevignani C., Dumitru C.D., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
9. Starczynowski D.T., Morin R., McPherson A., et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011, 117:595-607.
10. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010, 16:49-58.
11. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon.
12. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
13. Greenberg P.L., Tuechler H., Schanz J., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012, 120:2454-2465.
14. Pichiorri F., Suh S.S., Rocci A., et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010, 18:367-381.
15. Braun C.J., Zhang X., Savelyeva I., et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008, 68:10094-10104.
16. Zhai H., Karaayvaz M., Dong P., Sakuragi N., Ju J. Prognostic significance of miR-194 in endometrial cancer. Biomark Res 2013, 2013.
17. Sokol L., Caceres G., Volinia S., et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011, 153:24-32.
18. Mittal S.P., Mathai J., Kulkarni A.P., Pal J.K., Chattopadhyay S. miR-320a regulates erythroid differentiation through MAR binding protein SMAR1. Int J Biochem Cell Biol 2013, 45:2519-2529.
19. Hussein K., Theophile K., Busche G., et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010, 34:1169-1174.